Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
Cannaflos is a European biopharmaceutical company founded in Germany in 2019. It focuses on the endocannabinoid system and plant-derived cannabinoid medicines, covering the medical cannabis value chain “from plant to patient,” including genetic resources, cultivation and production, clinical research, compliance, and regulatory affairs. It is worth noting that the crawled content shows it is not a typical SaaS or enterprise software provider, but rather a company engaged in pharmaceutical R&D, product distribution, and professional services.
Its core capabilities include clinical-stage development of cannabinoid medicines, 19 EU-CPVO-registered cannabis cultivars, genetic licensing, in vitro germplasm preservation, mother plant renewal, cuttings, and feminized seed propagation services. The company also provides cultivation validation, commercialization support, market access, EU-GMP roadmaps, GxP networks, and consulting for pharmaceutical companies. For medical cannabis products, pharmacies can place orders through the German-language Fachbereich area for healthcare professionals; its products are associated with Bedrocan, CBD Pharma, Galaxia Life/PharmaRolly, and others.
The website does not disclose standard packages, subscription pricing, or payment methods. Product ordering requires access to the professional area, while genetic licensing and propagation services require further communication via forms or contacts. This clearly points to project-based delivery, B2B professional procurement, and regulatory licensing scenarios.
Its strengths lie in a strong compliance foundation, with emphasis on EU-GMP/EU-GDP, German AMG §§13 and 52a, and MedCanG §4 medical cannabis licenses, as well as attention to EMA/BfArM requirements. It also has traceable genetic resources and an academic collaboration network. The drawbacks are that there are no visible SaaS features such as workflows, permissions, APIs, cloud deployment, data dashboards, or third-party software integrations; commercial terms are also not transparent, and the healthcare professional area is German-only, creating a higher barrier for non-European customers.
It is better suited for pharmacies, licensed medical cannabis cultivators, pharmaceutical companies, clinical/preclinical R&D teams, and research institutions, rather than as a general enterprise software procurement option.
The text does not provide information on access from mainland China, so this is unknown.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on cannaflos.de official site.
cannaflos.de is an Germany Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach cannaflos.de directly.